论文信息 - A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge - 字舞流文

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge

Gregory D. Gromowski | E. Boritz | D. Douek | S. Peel | L. Jagodzinski | N. Michael | P. Thomas | A. Pekosz | S. Vasan | G. Matyas | V. Polonis | V. Dussupt | R. Sankhala | R. Seder | Ines Lakhal-Naouar | Amy R. Henry | J. Currier | M. Suthar | J. Darden | M. Rao | D. Paquin-Proulx | D. Bolton | K. Modjarrad | Jeffrey W. Froude | Xiankun Zeng | Rafael A. De La Barrera | H. Hack | L. Wieczorek | Maciel Porto | Agnes Hajduczki | S. Krebs | S. Daye | J. Wood | M. Gagne | Isabella Swafford | Alexander Anderson | Akshayaa Ganesh | S. Zarling | M. Dong | M. Joyce | E. Mokhtari | Michelle Zemil | Sandrine Soman | Wei-Hung Chen | Elizabeth J. Martinez | Caroline E Peterson | Hannah Grove | K. Wuertz | H. Hernandez | A. Winn | Kamil Radzyminski | P. Mudvari | S. Kar | M. Lewis | Erica K. Barkei | Caitlin Kuklis

[1] A. Sigal,et al. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection , 2021, medRxiv.

[2] Gregory D. Gromowski,et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity , 2021, bioRxiv.

[3] N. Michael,et al. A spike-ferritin nanoparticle vaccine induces robust innate immune activity and drives polyfunctional SARS-CoV-2-specific T cells , 2021, bioRxiv.

[4] R. Darnell,et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants , 2021, The New England journal of medicine.

[5] D. Ho,et al. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques , 2021, bioRxiv.

[6] D. Ho,et al. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates , 2021, bioRxiv.

[7] M. Beer,et al. CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 , 2021, bioRxiv.

[8] A. Godzik,et al. Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[9] A. Iafrate,et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.

[10] James D. Allen,et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection , 2021, Cell.

[11] D. Ho,et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.

[12] D. Ho,et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, bioRxiv.

[13] B. Graham,et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants , 2021, bioRxiv.

[14] Jie-Li Hu,et al. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies , 2021, Cellular & Molecular Immunology.

[15] M. Biggerstaff,et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[16] Larissa B. Thackray,et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein , 2021, Cell.

[17] L. Morris,et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, bioRxiv.

[18] D. Lauffenburger,et al. Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques , 2021, Nature.

[19] M. Nussenzweig,et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo , 2020, The Journal of experimental medicine.

[20] D. Lauffenburger,et al. Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[21] Sergei L. Kosakovsky Pond,et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa , 2020, medRxiv.

[22] Zhènglì Shí,et al. Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[23] Lisa E. Gralinski,et al. Animal models for COVID-19 , 2020, Nature.

[24] D. Lauffenburger,et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters , 2020, Nature medicine.

[25] J. Mascola,et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.

[26] Tokiko Watanabe,et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.

[27] R. Baric,et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[28] H. Yen,et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters , 2020, Nature.

[29] K. To,et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[31] Z. Beck,et al. Army Liposome Formulation (ALF) family of vaccine adjuvants , 2020, Expert review of vaccines.

[32] J. Luban. SARS-CoV-2 , 2020 .